CoChat

A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence

Open access
Laaksonen, E., Koski-Jännes, A., Salaspuro, M., Ahtinen, H., Alho, Hannu · 2008 · Alcohol and Alcoholism
Cited by 147

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

AIM: To compare the effects in alcohol-dependent patients of three pharmacotherapies, disulfiram (DIS), naltrexone (NTX), and acamprosate (ACA), when used with a brief manual-based cognitive-behavioural intervention. METHOD: We conducted a randomized, open label, multicentre naturalistic study in two phases; first, a 12-week continuously supervised medication, followed by targeted medication (TM) up to 52 weeks in addition to a 67-week follow-up period; altogether 119 weeks (2.5 years), in 243 voluntary treatment-seeking alcohol-dependent adult outpatients. Subjects were randomized 1:1:1 to receive supervised NTX, ACA or DIS, 50, 1998, or 200 mg, respectively, per day, plus a brief manual-based cognitive-behavioural intervention. The patients were met in the second and sixth weeks, and then after 3, 6, and 12 months. The primary outcome measures were the time (days) to first heavy drinking day (HDD), and time during the first 3 months to the first drinking day after medication started. Secondary variables were abstinent days/week (0 drinks/day), average weekly alcohol intake, Alcohol Use Disorder Identification Test (AUDIT), Severity of Alcohol Dependence Data (SADD), and quality of life (QL) measures. RESULTS: All three study groups showed marked reduction in drinking, from baseline to the end of the study. During the continuous medication phase, treatment with DIS was more effective in reducing HDDs and average weekly alcohol consumption, and increasing time to the first drink, as well as the number of abstinent days. During the TM period, there were no significant differences between the groups in time to first HDD and days to first drinking, but the abstinence days were significantly more frequent in the DIS group than ACA and NTX. There were no differences between the NTX and ACA groups in either phase of the study of drinking outcomes. However, SADD scores improved more in the NTX group than the ACA group. CONCLUSIONS: Patients allocated to ACA, NTX and DIS combined with brief manual-based cognitive behavioural intervention significantly reduce their alcohol consumption and report improved QL. Supervised DIS appeared superior, especially during the continuous medication period, to NTX and ACA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/alcalc/agm136

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 23

  1. Anton, 2001, Pharmacologic approaches to the management of alcoholism, Journal of Clinical Psychiatry, 62, 11
  2. Anton, 1999, Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial, American Journal of Psychiatry, 156, 1758, 10.1176/ajp.156.11.1758 · DOI · Paper page
  3. Berglund, 2003, Treatment of alcohol abuse: an evidence-based review, Alcoholism, Clinical and Experimental Research, 27, 1645, 10.1097/01.ALC.0000090144.99832.19 · DOI
  4. Bouza, 2004, Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review, Addiction, 99, 811, 10.1111/j.1360-0443.2004.00763.x · DOI · Paper page
  5. Brewer, 1987, Fact, fiction, finance and effectiveness in alcoholism treatment, British Journal of Clinical Practice. Symposium Supplement, 51, 39
  6. Brewer, 2003, Learning the language of abstinence in addiction treatment: some similarities between relapse-prevention with DIS, naltrexone, and other pharmacological antagonists and intensive “immersion” methods of foreign language teaching, Substance Abuse, 24, 157, 10.1080/08897070309511545 · DOI
  7. Chick, 2004, DIS: cautions on liver function; how to supervise, Addiction, 99, 25, 10.1111/j.1360-0443.2004.00610.x · DOI
  8. Chick, 2000, A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse, Alcohol and Alcoholism, 35, 587, 10.1093/alcalc/35.6.587 · DOI · Paper page
  9. Chick, 1992, DIS treatment of alcoholism, British Journal of Psychiatry, 161, 84, 10.1192/bjp.161.1.84 · DOI · Paper page
  10. Cunningham, 2001, Using self-help materials to motivate change at assessment for alcohol treatment, Journal of Substance Abuse Treatment, 20, 301, 10.1016/S0740-5472(01)00175-1 · DOI
  11. Davidson, 1986, The validity of the Short Alcohol Dependence Data (SADD) Questionnaire: a short self-report questionnaire for the assessment of alcohol dependence, British Journal of Addiction, 81, 217, 10.1111/j.1360-0443.1986.tb00319.x · DOI
  12. Heinala, 2001, Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial, Journal of Clinical Psychopharmacology, 21, 287, 10.1097/00004714-200106000-00006 · DOI · Paper page
  13. Hunt, 1973, A community-reinforcement approach to alcoholism, Behaviour Research and Therapy, 11, 91, 10.1016/0005-7967(73)90072-7 · DOI · Paper page
  14. Kiefer, 2003, Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study, Archives of General Psychiatry, 60, 92, 10.1001/archpsyc.60.1.92 · DOI · Paper page
  15. Koskenvuo, 1979, The Finnish Twin Registry Baseline Characteristics
  16. Kranzler, 2003, Targeted naltrexone for early problem drinkers, Journal of Clinical Psychopharmacology, 23, 294, 10.1097/01.jcp.0000084030.22282.6d · DOI · Paper page
  17. Kranzler, 2001, Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis, Alcoholism, Clinical and Experimental Research, 25, 1335, 10.1111/j.1530-0277.2001.tb02356.x · DOI · Paper page
  18. Laaksonen, 2007, Winning at Last—Defeating Drinking Problem. A medical and cognitive-behavioural program for the users of acamprosate, disulfiram and naltrexone, Alcohol and Alcoholism, 42
  19. Morley, 2006, Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial, Addiction, 101, 1451, 10.1111/j.1360-0443.2006.01555.x · DOI · Paper page
  20. O'Malley, 1996, Six-month follow-up of naltrexone and psychotherapy for alcohol dependence, Archives of General Psychiatry, 53, 217, 10.1001/archpsyc.1996.01830030039007 · DOI · Paper page
  21. Poikolainen, 1983, Diary gives more accurate information about alcohol consumption than questionnaire, Drug and Alcohol Dependence, 11, 209, 10.1016/0376-8716(83)90080-7 · DOI
  22. Srisurapanont, 2002, Opioid antagonists for alcohol dependence, Cochrane Database of Systematic Reviews, CD001867
  23. von Bardeleben, 1999, Randomized open efficacy study of Naltrexone vs. Acamprosate vs. DIS combined with cognitive-behavioral psychotherapy in preventing alcohol relapse, 45, 10.1159/000059537 · DOI

Cited by

See all 147

Metadata

Authors
Laaksonen, E., Koski-Jännes, A., Salaspuro, M., Ahtinen, H., & Alho, H.
Venue
Alcohol and Alcoholism
Published
2007-10-27
Volume
43
Issue
1
Pages
53-61
ISSN
  • 0735-0414 (ISSN-L)
  • 1464-3502
OpenAlex
W2141218546
Cited by
147
References
12
FWCI
6.28
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. https://app.cochat.ai/papers/10.1093/alcalc/agm136
The paper
Laaksonen, E., Koski-Jännes, A., Salaspuro, M., Ahtinen, H., & Alho, H. (2008). A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agm136

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.